Loading
A phase 3 trial of Mezigdomide, Carfilzomib, Dexamethasone in multiple myeloma, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) is a phase 3 interventional study registered as NCT05552976 by Bristol-Myers Squibb, with 606 participants enrolled, started 2023-01-10 and due to reach its primary completion in 2026-07-18. Interventions recorded: Mezigdomide, Carfilzomib, Dexamethasone. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.